*Five Years Citation in Google scholar (2016 - 2020) is. 1451*   *    IJPR IS INDEXED IN ELSEVIER EMBASE & EBSCO *       

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence
Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Descriptive Study of Hemophilia Person's Life and Care in Aldiwanyah Province/Iraq

Author: ABDULAZIZ WANNAS ABD, SUZAN SABBAR, MUTLAG
Abstract: Both hemophilia A & B are recessive, X- linked disease due to gene mutation, charge of clotting factor proteins needed for clot formation after bleeding episode. The study was aimed to evaluate the life quality and major problems of hemophilia patients. Analytic information from all (82) person with hemophilia A and 13 person of hemophilia B; all patients were male. We found that on demand treatment is carry high risk of recurrent bleeding episode if compared with prophylactic treatment specific challenges to maintain prophylactic treatment in regular way in spite of effort to convince hemophilia patients that prophylactic therapy prevent long term complications, hemophilia patients refuse regular regimen believing that continuous therapy lead to early onset complications. Target joint involvement in our study mainly occur in large joint like knee joint 59.09%,ankle joint(15.45%) and lesser joint involve was the shoulder joint(1.81%);also we found 4 patients of all 95 infected by hepatitis C and only one patient with human immunodeficiency virus ((HIV). The present study on people with hemophilia A with developed inhibitors (a small group) ;( 1) patient with mild inhibitors, 3 moderate inhibitors and 2 sever and only one patient with moderate inhibitors in hemophilia B. To improve the life quality, with recombinant factor VIII and factor IX as prophylaxis can prevent damage to the joint and reduce the rate of bleeding in the joint in hemophilia .intensive hemophilia care may be introduced the accomplishment of all hemophilia centers requirement like medications experts staff, physiotherapy, psychological support and family counseling.
Keyword: hemophilia a, hemophilia B, life quality.
DOI: https://doi.org/10.31838/ijpr/2021.13.01.297
Download: Request For Article
 




ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free